This week's View offers key points to remember from a review about the use of cardiovascular medications during pregnancy, key points to remember from the 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation, and highlights from a subsequent analysis of the ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) trial.

Subscribe on iTunes | Subscribe on Google Play

Clinical Topics: Acute Coronary Syndromes, Anticoagulation Management, Arrhythmias and Clinical EP, Cardiac Surgery, Cardiovascular Care Team, Congenital Heart Disease and Pediatric Cardiology, Diabetes and Cardiometabolic Disease, Dyslipidemia, Heart Failure and Cardiomyopathies, Invasive Cardiovascular Angiography and Intervention, Prevention, Valvular Heart Disease, Anticoagulation Management and ACS, Anticoagulation Management and Atrial Fibrillation, Implantable Devices, EP Basic Science, SCD/Ventricular Arrhythmias, Atrial Fibrillation/Supraventricular Arrhythmias, Cardiac Surgery and Arrhythmias, Cardiac Surgery and CHD and Pediatrics, Cardiac Surgery and Heart Failure, Cardiac Surgery and VHD, Congenital Heart Disease, CHD and Pediatrics and Arrhythmias, CHD and Pediatrics and Interventions, CHD and Pediatrics and Prevention, CHD and Pediatrics and Quality Improvement, Lipid Metabolism, Nonstatins, Novel Agents, Statins, Acute Heart Failure, Interventions and ACS, Interventions and Structural Heart Disease, Hypertension

Keywords: EaglesEyeView, AHA18, AHA Annual Scientific Sessions, ACC18, ACC Annual Scientific Session, Acute Coronary Syndrome, Adrenergic beta-Agonists, Angiotensin-Converting Enzyme Inhibitors, Angina, Unstable, Anti-Arrhythmia Agents, Antibodies, Monoclonal, Humanized, Apolipoproteins B, Arrhythmias, Cardiac, Anticoagulants, Atrial Fibrillation, Brain Ischemia, Aspirin, Catheter Ablation, Atrial Appendage, Cholesterol, HDL, Cholesterol, LDL, Diabetes Mellitus, Cost-Benefit Analysis, Coronary Disease, Dyslipidemias, Heart Failure, Gestational Age, Heart Valve Diseases, Heparin, Heparin, Low-Molecular-Weight, Hemorrhage, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Hypotension, Hypertension, Lipids, Monitoring, Ambulatory, Mitral Valve Stenosis, Myocardial Infarction, Myocardial Revascularization, Overweight, Obesity, Pharmacokinetics, Pre-Eclampsia, Prostaglandins, Platelet Aggregation Inhibitors, Risk Factors, Secondary Prevention, Stents, Pregnancy, Primary Prevention, Stroke, Stroke Volume, Renal Dialysis, Treatment Outcome, Warfarin, Women, Weight Loss, Wolff-Parkinson-White Syndrome

< Back to Listings